Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
The paper presents Psychedelic Harm Reduction and Integration (PHRI), a transtheoretical, transdiagnostic clinical model that combines harm-reduction psychotherapy and psychedelic-assisted psychotherapy to guide clinicians working with people who use or consider using psychedelics. PHRI emphasises compassionate, destigmatising care over abstinence-based paradigms and offers practical guidance for assessment, preparation and managing difficult experiences in both brief and ongoing therapy.
Authors
- Elizabeth Nielson
- Ingmar Gorman
Published
Abstract
Psychedelic Harm Reduction and Integration (PHRI) is a transtheoretical and transdiagnostic clinical approach to working with patients who are using or considering using psychedelics in any context. The ongoing discussion of psychedelics in academic research and mainstream media, coupled with recent law enforcement deprioritization of psychedelics and compassionate use approvals for psychedelic-assisted therapy, make this model exceedingly timely. Given the prevalence of psychedelic use, the therapeutic potential of psychedelics, and the unique cultural and historical context in which psychedelics are placed, it is important that mental health providers have an understanding of the unique motivations, experiences, and needs of people who use them. PHRI incorporates elements of harm reduction psychotherapy and psychedelic-assisted psychotherapy, and can be applied in both brief and ongoing psychotherapy interactions. PHRI represents a shift away from assessment limited to untoward outcomes of psychedelic use and abstinence-based addiction treatment paradigms and toward a stance of compassionate, destigmatizing acceptance of patients' choices. Considerations for assessment, preparation, and working with difficult experiences are presented.
Research Summary of 'Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice'
Introduction
Psychedelics are described as compounds and experiences that alter perception of the self and increase awareness of mental processes. Palhano-Fontes and colleagues situate Psychedelic Harm Reduction and Integration (PHRI) as a transtheoretical, transdiagnostic clinical framework that draws on harm reduction psychotherapy, psychedelic-assisted therapy, mindfulness-based modalities, and psychodynamic principles. The model is explicitly psychotherapeutic rather than pharmacological: it guides clinicians in preparing patients for, and integrating, non-ordinary states of consciousness (NOSCs) without administering psychedelics as part of treatment. The authors argue that growing public interest, rising rates of psychedelic use, and expanding clinical research make a cohesive, academically defined model for integration timely. PHRI aims to offer clinicians a compassionate, non-stigmatising stance that centres patient autonomy, broadens assessment beyond abstinence paradigms, and provides concrete therapeutic tasks for both pre‑experience preparation and post‑experience integration. This paper presents PHRI as the first cohesive theoretical framework for psychedelic integration in the peer‑reviewed literature and explains its scope and core elements.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- Authors
- APA Citation
Gorman, I., Nielson, E. M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021). Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Frontiers in Psychology, 12. https://doi.org/10.3389/fpsyg.2021.645246
References (49)
Papers cited by this study that are also in Blossom
Baggot, M. J. · Preprints (2015)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)
Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)
Show all 49 referencesShow fewer
Dorsen, C., Palamar, J., Shedlin, M. G. · Addiction Research and Theory (2018)
Elsey, J. W. B. · Drug Science Policy and Law (2017)
Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Hartogsohn, I. · Journal of Psychopharmacology (2016)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Hartogsohn, I. · Frontiers in Human Neuroscience (2018)
Hendricks, P. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Hendricks, P. S., Thorne, C. B., Clark, B. et al. · Journal of Psychopharmacology (2015)
Johansen, P. Ø., Krebs, T. S. · Journal of Psychopharmacology (2015)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)
Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V. et al. · Journal of Psychoactive Drugs (2007)
Kuypers, K. P. C. · Medical Hypotheses (2019)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Lawn, W., Hallak, J. E., Crippa, J. A. et al. · Scientific Reports (2017)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)
Nichols, D. E. · Pharmacological Reviews (2016)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Phelps, J. · Journal of Humanistic Psychology (2017)
Pisano, V. D., Putnam, N. P., Kramer, H. M. et al. · Journal of Psychopharmacology (2017)
Quednow, B. B., Kometer, M., Geyer, M. A. et al. · Neuropsychopharmacology (2011)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychopharmacology (2019)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Sloshower, J. A. · Plant Medicines Healing and Psychedelic Science (2018)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)
Cited By (27)
Papers in Blossom that reference this study
Calnan, M., Blest-Hopley, G., Busch, C. et al. · Brain and Behavior (2025)
Mathai, D. S., Roberts, D. E., Nayak, S. M. et al. · Journal of Psychedelic Drugs (2025)
Neitzke-Spruill, L., Beit, C., Robinson, J. et al. · Neuroethics (2024)
Robinson, O., Evans, J., Luke, D. et al. · Frontiers in Psychology (2024)
Cassidy, K., Healy, C. J., Henje, E. et al. · Drug Science Policy and Law (2024)
Marrocu, A., Kettner, H., Weiss, B. et al. · Journal of Psychopharmacology (2024)
Argyri, E. K., Evans, J., Luke, D. et al. · SSRN (2024)
Jacobs, E., Murphy-Beiner, A., Rouiller, I. et al. · Neuroethics (2023)
Evans, J., Robinson, O., Ketzitzidou-Argyri, E. et al. · PLOS ONE (2023)
Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)
Show all 27 papersShow fewer
Bremler, R., Katati, N., Shergill, P. et al. · Scientific Reports (2023)
Pleet, M. M., White, J., Zamaria, J. A. et al. · Psychedelic Medicine (2023)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)
Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)
Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)
Lutkajtis, A., Evans, J. · Journal of Psychedelic Studies (2023)
Wolfson, P. E. · Journal of Psychedelic Studies (2023)
Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)
Basedow, L. A., Kuitunen-Paul, S. · Drug and Alcohol Review (2022)
Belser, A. B. · Frontiers in Psychology (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2022)
Earleywine, M., Low, F., Lau, C. et al. · Journal of Humanistic Psychology (2022)
Pots, W., Chakhssi, F. · Frontiers in Psychology (2022)
Whitfield, H. J. · Frontiers in Psychiatry (2021)
Jylkkä, J. · ACS Pharmacology and Translational Science (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.